Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
US11220523B2 · kind B2 · utility
0Cited by
22References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2020 |
| Grant date | Jan 11, 2022 |
| Priority date | — |
| Expiry date | Apr 14, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/285
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of anti-MAG neuropathy. In particular, the invention relates to disaccharides of formula (I) and (II) wherein Z is optionally substituted phenyl, heteroaryl, arylcarbonyl, or heteroarylmethyl, and to therapeutically acceptable polymers comprising a multitude of substituents of formula (I) and/or formula (II), wherein Z is a bifunctional linker connecting the disaccharides to the polymer backbone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.